B Cell Activating Factor Gene Polymorphisms in Patients With Risk of Idiopathic Thrombocytopenic Purpura

2011 ◽  
Vol 342 (1) ◽  
pp. 9-14 ◽  
Author(s):  
Samah M. Abdel-Hamid ◽  
Hend N. Al-Lithy
Blood ◽  
2008 ◽  
Vol 112 (4) ◽  
pp. 1147-1150 ◽  
Author(s):  
Roberto Stasi ◽  
Nichola Cooper ◽  
Giovanni Del Poeta ◽  
Elisa Stipa ◽  
Maria Laura Evangelista ◽  
...  

Abstract The effects of B-cell depletion with rituximab on regulatory T cells (Tregs) have not been determined. We investigated Tregs in patients receiving rituximab for chronic idiopathic thrombocytopenic purpura (ITP). The peripheral blood Tregs, identified as CD4+FOXP3+ T cells, were measured by flow cytometry prior to and after the immunotherapy. In addition, Tregs were analyzed for their usage of the T-cell receptor (TCR) β-variable (VB) region gene as well as their regulatory function as assessed by cell proliferation assays. Pretreatment data revealed a reduced number and a defective suppressive capacity of Tregs in ITP patients compared with control individuals. In addition, Tregs showed a polyclonal spectratype. Patients, particularly responders, showed restored numbers of Tregs as well as a restored regulatory function upon treatment with rituximab. These results indicate that patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell–targeted therapy.


Blood ◽  
1990 ◽  
Vol 76 (11) ◽  
pp. 2321-2326 ◽  
Author(s):  
D van der Harst ◽  
D de Jong ◽  
J Limpens ◽  
PM Kluin ◽  
Y Rozier ◽  
...  

Idiopathic thrombocytopenic purpura (ITP) may be associated with other autoimmune diseases and the development of lymphoproliferative malignancies. In Sjogren's disease, Graves' disease, and essential mixed cryoglobulinemia, which are also associated with the development of B-cell neoplasia, clonal B-cell expansions have been detected. Eleven patients with ITP were investigated for the presence of a clonal excess (CE) using kappa-lambda flow cytometry and DNA analysis for rearrangement of immunoglobulin heavy and light chain genes in blood and/or spleen lymphocytes. In 10 of 11 patients, clonal B-cell populations were found by one or both tests. In three of these patients, oligoclonal B-cell populations were suggested by the combined findings. In all four patients with a small paraproteinemia, the isotype was confirmed by either flow cytometry or DNA rearrangement analysis. Our data suggest that the oligoclonal expansions are not restricted to CD5+ B cells, as in the majority of patients this subset was below the detection level of flow cytometry or DNA rearrangement analysis. None of the patients developed clinical manifestations of malignant lymphoma during a follow-up period of 10 to 44 months after sampling. We conclude that clonal excess populations of B cells are not a unique feature of malignant lymphoma, but may occur in autoimmune diseases, suggesting a benign (oligo)clonal B-cell proliferation.


2016 ◽  
Vol 22 ◽  
pp. 2086-2096 ◽  
Author(s):  
Jiannan Xu ◽  
Liyun Zhao ◽  
Yan Zhang ◽  
Qingxu Guo ◽  
Hui Chen

Sign in / Sign up

Export Citation Format

Share Document